| Objective:the difference of diabetic patients and normal glucose tolerance subjects in clinical metabolic markers,diabetic patients and normal glucose tolerance subjects were divided to four subset,and analysing Asprosin concentration’s difference of four subset.exploring effects of dapagliflozin on fasting plasma glucose,weight,lipid metabolism,and Asprosin of overweigt or obese type 2 diabetic patients futher.Methods:type 2 diabetes mellitus patients who were admitted to inpatient,outpatient department of the Affiliated Nanhua Hospital of University of South China from June 2019 to December 2019 were selected as the study subjects.Type 2 diabetes mellitus patients of 44(A)cases,40 cases normal glucose tolerance subjects(B)as normal control.With the BMI≥25kg/m~2 as the cutting point,the type 2 diabetes mellitus group divide into overweigt or obese(a1)and non-obese(a2)subgroup.normal glucose tolerance group divide into overweigt or obese(b1)and non-obese(b2)subgroup.On the basis of the poor plasma glucose control of the original hypoglycemic drugs of the treatment group,10mg oral dapagliflozin daily was given for 12 weeks,measuring the clinical metabolic markers of diabetic group’s before and after treatment and normal glucose tolerance subjects,including fasting plasma glucose,Fasting insulin,glycosylated hemoglobin,HOMA-IR(HOMA-IR is equal to the weight divided by the square of height),weight,BMI,waist circumference,total cholesterol,triglyceride,high density lipoprotein cholestrol,low density lipoprotein cholesterol,systolic blood pressure,diastolic blood pressure,Asprosin.The difference of diabetic patients with non-obese or obesity and normal glucose tolerance sujects in clinical metabolic markers,and analysing Asprosin concentration’s difference of diabetic patients(patients with overweigt or obese and non-obese)and normal glucose tolerance subjects(subjects with overweigt or obese and non-obese),analysing effects of dapagliflozin on Fasting plasma glucose,weight,BMI,lipid metabolism and Asprosin of overweigt or obese type 2diabetic patients.Results:1.Level of waist circumference,glycosylated hemoglobin,fasting plasma glucose in A group highter than B group(Wc:91.68±10.23cm vs86.10±6.58cm;HbA1c:8.71±2.05%vs 5.26±0.52%;FPG:10.06±3.45mmol/L vs 5.04±0.52mmol/L,P<0.05).High density lipoprotein cholestrol in A group was lower than B group(1.15±0.47mmol/L vs 1.56±0.73mmol/L,P<0.05).2.Level of Asprosin in A group was higher than B group(528.37±58.83pg/ml vs 402.24±61.67pg/ml,P<0.05).Level of Asprosin of a1group(562.76±32.79pg/ml),a2 group(496.97±60.23pg/ml),b1 group(445.75±42.34pg/ml),b2 group(373.23±55.53pg/ml)in four subgroups were significantly different(P<0.05).3.The comparison of clinical indicators before and after treatment between the a1 group and a2 group showed that the concentrations of fasting blood glucose,glycosylated hemoglobin,body weight,systolic blood pressure,triglycerides,and serum Asprosin were lower than before,High density lipoprotein cholesterol was higher than before(P<0.05).After treatment,the change of waist circumference,body mass index,diastolic blood pressure,total cholesterol,low density lipoprotein cholestrol,HOMA-IR in two groups was not significant difference(P>0.05).4.Univariate correlation analysis indicated serum Asprosin of type 2diabetes mellitus patients were positively correlated with fasting plasma glucose,glycosylated hemoglobin,waist circumference,triglyceride,HOMA-IR.It were a negative correlation between serum Asprosin and high density lipoprotein cholestrol.Conclusion:After T2DM patients gived dapagliflozin treatment,not only overweigt or obese T2DM patients’s plasma glucose and weight were lower than before,but also blood lipid indicated triglyceride was lower than before,high density lipoprotein cholestrol was highter than before.Level of Asprosin was lower than before,it was suggested that serum Asprosin may played a role in T2DM patients improved metabolic disorders by giving dapagliflozin. |
PDF Full Text Request